PT-141 10mg

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist originally developed as a research compound under the designation PT-141. It is structurally related to melanocortin peptides and has been studied extensively in research involving melanocortin receptor signaling and peptide–receptor interactions.

Alph4Labs’ PT-141 is supplied as a research compound with batch-specific analytical documentation supporting identity, purity, and traceability. It is intended strictly for laboratory and scientific research purposes and is not supplied as an approved pharmaceutical product.

Scientific Name

Bremelanotide (PT-141) — synthetic cyclic heptapeptide melanocortin receptor agonist

Peptide sequence: Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH₂Condensed sequence: XDHFRWK

Specifications

• Product: PT-141 / Bremelanotide

• Quantity: 10mg

• Form: Lyophilized research compound

• CAS Number: 189691-06-3

• Molecular Formula: C₅₀H₆₈N₁₄O₁₀

• Molecular Weight: 1025.2 g/mol (free-base molecular weight)

• Purity: >99% UK independent external laboratory verified*

• Storage: Refrigerated and protected from light

• Traceability: Unique batch reference

• Documentation: Batch-specific analytical verification

The molecular identity and free-base specifications above are reported by PubChem and the FDA Substance Registration System. PT-141/bremelanotide may also be supplied in salt forms such as bremelanotide acetate, which have different molecular weights and formulas. The exact salt/form should therefore be confirmed against the batch-specific CoA before publishing the final specification.

Research Grade

PT-141 is studied primarily in connection with melanocortin receptor biology, including receptor activation, peptide–receptor interactions, intracellular signaling pathways, and related molecular mechanisms.

Bremelanotide has an established pharmaceutical history and received FDA approval in 2019 under the brand Vyleesi for a specific clinical indication. The Alph4Labs research product should not be represented as Vyleesi, as an equivalent pharmaceutical product, or as being approved for human use.

Highlights

• FREE Shipping on all products

• Ships within 24 hours

• >24 months shelf life*

• >99% purity — independently verified by a UK external laboratory*

• Batch-specific traceability

• Analytical documentation supporting identity and purity

• Research focused on melanocortin receptor signaling

• Professionally handled and packaged as a research compound
  

PRODUCT USE DISCLAIMER

For research purposes only.

PT-141 / Bremelanotide supplied by Alph4Labs is intended strictly for laboratory and scientific research. It is not intended for human or veterinary use, self-administration, consumption, diagnosis, treatment, prevention of disease, or as a pharmaceutical product.

Alph4Labs does not represent this research product as Vyleesi or as an FDA-approved medicine. Vyleesi (bremelanotide injection) is an FDA-approved prescription drug with specific labeled indications, dosage forms, contraindications, and safety information.

*Purity, shelf life, analytical testing, and storage specifications should be verified against the applicable batch-specific Certificate of Analysis (CoA).